Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.57
REGN's Cash to Debt is ranked higher than
59% of the 1493 Companies
in the Global Biotechnology industry.

( Industry Median: 48.04 vs. REGN: 1.57 )
REGN' s 10-Year Cash to Debt Range
Min: 0.57   Max: No Debt
Current: 1.57

Equity to Asset 0.71
REGN's Equity to Asset is ranked higher than
75% of the 1113 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. REGN: 0.71 )
REGN' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.93
Current: 0.71

0.18
0.93
Interest Coverage 22.43
REGN's Interest Coverage is ranked higher than
51% of the 680 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. REGN: 22.43 )
REGN' s 10-Year Interest Coverage Range
Min: 0.46   Max: 22.43
Current: 22.43

0.46
22.43
F-Score: 4
Z-Score: 28.00
M-Score: -2.53
WACC vs ROIC
7.19%
17.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 30.56
REGN's Operating margin (%) is ranked higher than
96% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -79.37 vs. REGN: 30.56 )
REGN' s 10-Year Operating margin (%) Range
Min: -554.63   Max: 187.97
Current: 30.56

-554.63
187.97
Net-margin (%) 11.71
REGN's Net-margin (%) is ranked higher than
90% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. REGN: 11.71 )
REGN' s 10-Year Net-margin (%) Range
Min: -565.66   Max: 54.43
Current: 11.71

-565.66
54.43
ROE (%) 14.18
REGN's ROE (%) is ranked higher than
94% of the 1371 Companies
in the Global Biotechnology industry.

( Industry Median: -28.22 vs. REGN: 14.18 )
REGN' s 10-Year ROE (%) Range
Min: -75.77   Max: 86.68
Current: 14.18

-75.77
86.68
ROA (%) 9.68
REGN's ROA (%) is ranked higher than
94% of the 1497 Companies
in the Global Biotechnology industry.

( Industry Median: -22.65 vs. REGN: 9.68 )
REGN' s 10-Year ROA (%) Range
Min: -28.05   Max: 44.08
Current: 9.68

-28.05
44.08
ROC (Joel Greenblatt) (%) 56.55
REGN's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. REGN: 56.55 )
REGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -214.91   Max: 168.03
Current: 56.55

-214.91
168.03
Revenue Growth (3Y)(%) 71.60
REGN's Revenue Growth (3Y)(%) is ranked higher than
97% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. REGN: 71.60 )
REGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -25.3   Max: 81.3
Current: 71.6

-25.3
81.3
» REGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

REGN Guru Trades in Q2 2014

Mario Gabelli 2,295 sh (New)
Joel Greenblatt 881 sh (New)
Jim Simons 2,862 sh (New)
Ray Dalio 18,400 sh (New)
Andreas Halvorsen 2,963,456 sh (+181.75%)
Vanguard Health Care Fund 2,795,500 sh (+60.34%)
Frank Sands 4,907,362 sh (+22.32%)
Ron Baron 7,109 sh (+16.85%)
Steven Cohen 14,500 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q3 2014

REGN Guru Trades in Q3 2014

Paul Tudor Jones 2,499 sh (New)
Ken Fisher 583 sh (New)
Jim Simons 26,562 sh (+828.09%)
Steven Cohen 23,600 sh (+62.76%)
Joel Greenblatt 1,410 sh (+60.05%)
Frank Sands 4,967,466 sh (+1.22%)
Ron Baron 7,109 sh (unchged)
Vanguard Health Care Fund 2,795,500 sh (unchged)
Mario Gabelli 2,190 sh (-4.58%)
Andreas Halvorsen 1,080,682 sh (-63.53%)
Ray Dalio 1,600 sh (-91.30%)
» More
Q4 2014

REGN Guru Trades in Q4 2014

Ray Dalio 11,800 sh (+637.50%)
Ron Baron 7,490 sh (+5.36%)
Vanguard Health Care Fund 2,921,000 sh (+4.49%)
Frank Sands 4,986,177 sh (+0.38%)
Frank Sands 4,986,177 sh (+0.38%)
Mario Gabelli 2,190 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen Sold Out
Jim Simons Sold Out
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 524 sh (-10.12%)
» More
Q1 2015

REGN Guru Trades in Q1 2015

Pioneer Investments 482 sh (New)
Jim Simons 167,488 sh (New)
Ken Fisher 534 sh (+1.91%)
Frank Sands 5,010,161 sh (+0.48%)
Vanguard Health Care Fund 2,921,000 sh (unchged)
Ron Baron 7,490 sh (unchged)
Mario Gabelli 2,190 sh (unchged)
Ray Dalio Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with REGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 163.30
REGN's P/E(ttm) is ranked higher than
87% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 163.30 )
REGN' s 10-Year P/E(ttm) Range
Min: 9.83   Max: 163.34
Current: 163.3

9.83
163.34
Forward P/E 39.53
REGN's Forward P/E is ranked higher than
89% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 39.53 )
N/A
PE(NRI) 164.20
REGN's PE(NRI) is ranked higher than
89% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 164.20 )
REGN' s 10-Year PE(NRI) Range
Min: 10.65   Max: 164.18
Current: 164.2

10.65
164.18
P/B 17.86
REGN's P/B is ranked lower than
51% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. REGN: 17.86 )
REGN' s 10-Year P/B Range
Min: 1.43   Max: 26.42
Current: 17.86

1.43
26.42
P/S 19.25
REGN's P/S is ranked higher than
68% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 40.71 vs. REGN: 19.25 )
REGN' s 10-Year P/S Range
Min: 2.06   Max: 27.97
Current: 19.25

2.06
27.97
PFCF 266.26
REGN's PFCF is ranked higher than
90% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 266.26 )
REGN' s 10-Year PFCF Range
Min: 9.29   Max: 2102
Current: 266.26

9.29
2102
POCF 97.51
REGN's POCF is ranked higher than
90% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 97.51 )
REGN' s 10-Year POCF Range
Min: 7.52   Max: 359.87
Current: 97.51

7.52
359.87
EV-to-EBIT 56.41
REGN's EV-to-EBIT is ranked higher than
92% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 56.41 )
REGN' s 10-Year EV-to-EBIT Range
Min: -106.3   Max: 2827.2
Current: 56.41

-106.3
2827.2
Shiller P/E 330.25
REGN's Shiller P/E is ranked higher than
92% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 330.25 )
REGN' s 10-Year Shiller P/E Range
Min: 270.6   Max: 1446.63
Current: 330.25

270.6
1446.63
Current Ratio 4.31
REGN's Current Ratio is ranked higher than
73% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.49 vs. REGN: 4.31 )
REGN' s 10-Year Current Ratio Range
Min: 2.17   Max: 20.69
Current: 4.31

2.17
20.69
Quick Ratio 4.06
REGN's Quick Ratio is ranked higher than
73% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. REGN: 4.06 )
REGN' s 10-Year Quick Ratio Range
Min: 2.17   Max: 20.5
Current: 4.06

2.17
20.5
Days Inventory 172.38
REGN's Days Inventory is ranked higher than
84% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 172.38 )
REGN' s 10-Year Days Inventory Range
Min: 61.88   Max: 432.93
Current: 172.38

61.88
432.93
Days Sales Outstanding 121.05
REGN's Days Sales Outstanding is ranked higher than
74% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 141.98 vs. REGN: 121.05 )
REGN' s 10-Year Days Sales Outstanding Range
Min: 6.35   Max: 201.38
Current: 121.05

6.35
201.38

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 48.94
REGN's Price/Net Current Asset Value is ranked higher than
59% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 48.94 vs. REGN: 48.94 )
REGN' s 10-Year Price/Net Current Asset Value Range
Min: 3.12   Max: 157.38
Current: 48.94

3.12
157.38
Price/Tangible Book 17.86
REGN's Price/Tangible Book is ranked lower than
51% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 10.70 vs. REGN: 17.86 )
REGN' s 10-Year Price/Tangible Book Range
Min: 1.73   Max: 16.53
Current: 17.86

1.73
16.53
Price/DCF (Projected) 20.84
REGN's Price/DCF (Projected) is ranked higher than
89% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 20.84 )
REGN' s 10-Year Price/DCF (Projected) Range
Min: 14.99   Max: 240.67
Current: 20.84

14.99
240.67
Price/Median PS Value 1.71
REGN's Price/Median PS Value is ranked higher than
74% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. REGN: 1.71 )
REGN' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 4.72
Current: 1.71

0.2
4.72
Price/Graham Number 10.84
REGN's Price/Graham Number is ranked higher than
87% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. REGN: 10.84 )
REGN' s 10-Year Price/Graham Number Range
Min: 1.24   Max: 9.52
Current: 10.84

1.24
9.52
Earnings Yield (Greenblatt) 1.80
REGN's Earnings Yield (Greenblatt) is ranked higher than
90% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. REGN: 1.80 )
REGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 24.9
Current: 1.8

1.3
24.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:REGN.Switzerland,
Regeneron Pharmaceuticals Inc was incorporated in in the State of New York on January 1988. The Company is a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The Company's preclinical research programs are in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. Its manufacturing facilities are located in Rensselaer, New York and consist of three buildings totaling approximately 490,000 square feet of research, manufacturing, office, and warehouse space. It currently has approximately 74,000liters of cell culture capacity at these facilities. It faces competition from pharmaceutical, biotechnology, and chemical companies. Its competitors are Genentech, Novartis, Pfizer Inc., Bayer HealthCare, Onyx Pharmaceuticals, Inc., Eli Lilly and Company, Abbott, sanofi-aventis, Merck & Co., Amgen Inc., Roche, and others. Its present and future business would be subject to regulation under the United States Atomic Energy Act, the Clean Air Act, the Clean Water Act, the Comprehensive Environmental Response, Compensation and Liability Act, the National Environmental Policy Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, national restrictions, and other current and potential future local, state, federal, and foreign regulations.
» More Articles for REGN

Headlines

Articles On GuruFocus.com
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
1 Feb 23 2015 
1 Feb 23 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
S&P 500 Finishes Above 2,000 Aug 27 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA Feb 17 2014 
Insiders Are Buying Ophthotech Oct 08 2013 

More From Other Websites
The Most Loved Biotechs of Big Hedge Funds May 23 2015
What You May Have Missed in Biotech: Eye Drug Fails, Ear Drug Flops, and Herpes Drug Succeeds May 23 2015
3 Top IBD 50 Stocks Hit New All-Time Highs May 21 2015
Regeneron-Sanofi's Sarilumab Meets Endpoints in Phase III - Analyst Blog May 21 2015
Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in... May 21 2015
Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Studies with Sarilumab in... May 21 2015
Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in... May 21 2015
Cramer: This is the absolute worst thing in this market May 20 2015
Cramer: Bail out now on this group May 20 2015
Jim Cramer -- Regeneron Will Go Higher; Sarepta Is Rallying May 20 2015
Move Over Chip Stocks: Here Are 5 Top Biotechs May 20 2015
10 S&P 500 Companies to Have the Most Revenue Growth in 2015 May 20 2015
Cramer's Mad Dash: Regeneron goes higher May 20 2015
Cramer: This went from $5 to $500 and isn't done May 19 2015
Healthcare Winners and Losers: May 19, 2015 May 19 2015
Regeneron/Sanofi Announce Positive Data on Dupilumab - Analyst Blog May 19 2015
Regeneron Shares Seen Reaching $525 May 19 2015
Sanofi and Regeneron Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the... May 18 2015
Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the... May 18 2015
Regeneron: Why It's Heading to $550 May 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK